SCHEMBL13329561

SCHEMBL13329561

Cc1nc2c(c(=O)n1C(c1ccccc1)c1ccccc1)CN(C)CC2

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.42
MAPT P10636 4/20 0.42
ALDH1A1 P00352 3/20 0.42
MEN1 O00255 3/20 0.42
KDM4E B2RXH2 3/20 0.42
HPGD P15428 1/20 0.42
MTHFD2 P13995 1/20 0.39
HTR6 P50406 1/20 0.39
CCR5 P51681 1/20 0.38
HTR2A P28223 2/20 0.37
CHRM2 P08172 1/20 0.37
CHRM4 P08173 1/20 0.37
CHRM5 P08912 1/20 0.37
ADRA2A P08913 1/20 0.37
ADORA3 P0DMS8 1/20 0.37
CYP2D6 P10635 1/20 0.37
CHRM1 P11229 1/20 0.37
CHRM3 P20309 1/20 0.37
DRD1 P21728 1/20 0.37
ADRA1D P25100 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14046797 0.86 MAPT (0.44) KMT2AMAPTALDH1A1MEN1KDM4E
SCHEMBL14046930 0.86 ALDH1A1 (0.39) KMT2AMAPTALDH1A1MEN1KDM4E
SCHEMBL13329353 0.84 ALDH1A1 (0.46) KMT2AALDH1A1KDM4EMTHFD2HTR2A
SCHEMBL13360732 0.84 MTHFD2 (0.46) KMT2AMTHFD2CCR5
SCHEMBL13328991 0.83 CLPP (0.45) KMT2AMEN1KDM4EDRD3CYP2C9
SCHEMBL13328799 0.82 CYP1A2 (0.53) KMT2AMEN1CYP2C9CYP1A2
SCHEMBL13329014 0.82 HTR5A (0.41) MAPTCYP2D6SLC6A3CYP2C19CYP2C9
SCHEMBL13329041 0.82 CYP3A4 (0.39) KMT2AALDH1A1MEN1KDM4ECYP2C9
SCHEMBL13329016 0.82 KDM4E (0.39) KMT2AALDH1A1MEN1KDM4ECYP2D6
SCHEMBL13329097 0.81 MAOB (0.38) KMT2AALDH1A1KDM4EMTHFD2CCR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8318751-B2 Pyrimidinone derivatives and methods of use thereof MERCK SHARP & DOHME CORP. (US) 2012-11-27 US disclosed
US-20100113487-A1 PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF MERCK SHARP & DOHME CORP. 2010-05-06 US disclosed
WO-2008130584-A1 PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF SCHERING CORPORATION (US) 2008-10-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113487-A1 PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF GPR119, GPR180, GPR17 KMT2A 2184/4885MAPT 4832/4885ALDH1A1 748/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.